Gestofit 100 Injection contains natural micronized progesterone at a concentration of 100 mg per dose, formulated for intramuscular administration. Progesterone is a key endogenous steroid hormone involved in the regulation of the menstrual cycle, maintenance of pregnancy, and modulation of the endometrial environment. Gestofit 100 Injection is primarily indicated for the treatment of progesterone deficiency states, including luteal phase support in assisted reproductive technology (ART) protocols such as in vitro fertilization (IVF), prevention of threatened miscarriage, and management of amenorrhea due to progesterone insufficiency. The natural micronized form ensures enhanced bioavailability and mimics physiological progesterone activity. Upon intramuscular injection, Gestofit 100 facilitates endometrial transformation, promotes uterine quiescence, and supports early gestational development. The injection should be administered under medical supervision, with dosage and duration tailored according to the clinical indication and patient response. Common adverse effects may include injection site pain, mild sedation, and allergic reactions, though these are generally infrequent. Caution is advised in patients with hypersensitivity to progesterone or any component of the formulation. Gestofit 100 Injection is contraindicated in cases of known progesterone-dependent neoplasms, unexplained vaginal bleeding, and active thromboembolic disorders. Proper patient evaluation and monitoring are essential to ensure therapeutic efficacy and safety.